Colorectal cancer remains a leading cause of cancer-related deaths, necessitating the identification of novel therapeutic targets. The presence of tumor angiogenesis, the formation of new blood vessels from pre-existing ones, is crucial for tumor growth and metastasis. This process is heavily regulated by angiogenic factors, and the new evidence supporting EYA1’s involvement adds a critical piece to the cancer biology puzzle. EYA1 acts as a transcriptional co-activator, which enhances the expression of pro-angiogenic factors, thereby orchestrating the angiogenic response in tumors.

One of the most fascinating aspects of EYA1’s role lies in its regulation of HIF-1β, a central player in the cellular response to hypoxia. Under low-oxygen conditions, HIF-1β promotes the expression of various genes that aid in angiogenesis. The study revealed that EYA1 enhances HIF-1β transcriptional activity, which leads to increased levels of vascular endothelial growth factor (VEGF). VEGF is a potent angiogenic factor that stimulates endothelial cell proliferation and migration, thus facilitating the formation of new blood vessels necessary for tumor sustenance.

The molecular mechanics behind this process involve the demethylation of histones, specifically mediated by LSD2. Histones are proteins around which DNA winds, influencing gene expression through chemical modifications such as methylation. LSD2’s role as a demethylase is particularly interesting; it removes methyl groups from H3K4me2, a mark associated with active transcription, thus enhancing the transcription of HIF-1β. This mechanism elegantly illustrates how EYA1, via LSD2, can alter the epigenetic landscape in colorectal cancer, ultimately promoting tumor angiogenesis.

In colorectal cancer cells, the expression of EYA1 correlates with increased angiogenic activity, suggesting that targeting EYA1 could be a promising strategy in cancer therapy. Researchers used various in vitro and in vivo models to demonstrate that silencing EYA1 led to a significant reduction in the expression of angiogenic factors and a concomitant decrease in endothelial cell proliferation. This reduction logically translates to diminished tumor growth and metastasis, reinforcing the idea that EYA1 serves as a potential therapeutic target.

This study not only elucidates essential molecular interactions within colorectal cancer but also establishes a foundation for future therapeutic interventions. By inhibiting EYA1, it may be possible to disrupt the angiogenic capabilities of tumors, providing a novel approach to cancer treatment that could improve patient outcomes. Furthermore, understanding the specific pathways and mechanisms that underlie these interactions can lead to the development of small molecules or biological agents that effectively target EYA1 and its associated pathways.

The clinical implications of these findings are profound. Current therapies often target existing angiogenic pathways but may overlook other critical regulatory mechanisms such as those involving EYA1 and LSD2. By focusing on these newer targets, researchers may develop more robust and effective treatment options. The findings could pave the way for clinical trials aimed at assessing the safety and efficacy of EYA1 inhibitors in patients with colorectal cancer.

Moreover, the role of epigenetics in cancer biology cannot be overstated. The demethylation processes facilitated by LSD2 emphasize how modifications at the histone level can translate into significant changes in gene expression. With an increasing understanding of these epigenetic regulators, there is a potential to develop therapies that not only target DNA but also the proteins affecting gene accessibility and expression.

Future research will undoubtedly seek to explore the broader implications of EYA1’s role in other cancer types as well. While colorectal cancer serves as the focal point of this study, EYA1’s involvement in other malignancies could open new pathways for understanding tumor biology across a spectrum of cancers. The cross-talk between EYA1, LSD2, and various other signaling pathways could reveal intricate networks that govern tumorigenesis.

As the landscape of cancer research continues to evolve, studies like that of Cai et al. are critical in shaping our understanding of complex biological systems. This research emphasizes the necessity of investigating less conventional pathways that contribute to tumor progression in order to formulate effective treatment strategies. There remains optimism that interventions targeting these new axes of tumor biology will lead to breakthroughs in the management of colorectal cancer and potentially other malignancies as well.

The collaborative effort of the research team reflects the interdisciplinary nature of modern cancer research, integrating molecular biology, genetics, and therapeutic development. Their results call for further exploration and validation in clinical settings. As we strive towards personalized medicine, understanding the nuances of tumor biology will be essential in tailoring effective interventions for individual patients.

In summary, the role of EYA1 in promoting angiogenesis through HIF-1β activation and LSD2-mediated demethylation presents a powerful narrative about the intricacies of cancer progression. Continued research in this domain will likely yield significant insights that could eventually transform therapeutic approaches to colorectal cancer and beyond. This work serves as a stepping stone toward a deeper understanding of cancer biology, with the potential to impact clinical strategies aimed at combating one of the most challenging health crises of our time.

Subject of Research: EYA1’s role in tumor angiogenesis in colorectal cancer.

Article Title: EYA1 promotes tumor angiogenesis in colorectal cancer by activating HIF-1β through LSD2-mediated H3K4me2 demethylation.

Article References:

Cai, S., Wu, J., Wang, N. et al. EYA1 promotes tumor angiogenesis in colorectal cancer by activating HIF-1β through LSD2-mediated H3K4me2 demethylation. J Cancer Res Clin Oncol 151, 278 (2025). https://doi.org/10.1007/s00432-025-06270-2

Image Credits: AI Generated

DOI: 10.1007/s00432-025-06270-2

Keywords: EYA1, tumor angiogenesis, colorectal cancer, HIF-1β, LSD2, demethylation, VEGF, epigenetics.

In a stark contrast to physiological angiogenesis, which follows a meticulously orchestrated program involving sprouting and maturation of blood vessels, tumor angiogenesis is profoundly chaotic and disorganized. The review elucidates that the endothelial cells populating the tumor vasculature emanate not only from pre-existing adjacent blood vessels but also from an array of unexpected progenitor sources. Bone marrow-derived endothelial progenitor cells (EPCs) can home to tumor sites and differentiate into functional vascular endothelium, contributing to aberrant vessel formation. Moreover, the startling plasticity of cancer stem cells, capable of transdifferentiating into endothelial-like cells, adds another layer of complexity to the tumor vascular milieu.

Beyond the classical endothelial lineage, the review highlights emerging evidence of transdifferentiation events involving non-endothelial cellular players within the tumor microenvironment. Cancer-associated fibroblasts (CAFs), widely recognized for their roles in matrix remodeling and signaling, exhibit potential to assume endothelial characteristics under hypoxic conditions. Similarly, immature dendritic cells, traditionally considered immune sentinels, may transdifferentiate into endothelial-like cells, further amplifying vascular heterogeneity. These revelations underscore a fundamental deviation in tumor vasculature genesis, emphasizing the plasticity and adaptability of cellular constituents under pathological stimuli.

One of the most formidable barriers to successful vascular-targeted therapies lies in the intrinsic heterogeneity and adaptability of tumor blood vessels. Unlike structurally and functionally stable vessels in normal tissue, tumor blood vessels are irregular, leaky, and structurally aberrant. The review carefully dissects the molecular underpinnings that orchestrate this disarray, particularly how dysregulated signaling pathways influence endothelial cell behavior. The vascular endothelial growth factor (VEGF) family remains a centerpiece in angiogenic signaling; however, the interplay with platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and the angiopoietin-Tie2 axis creates a signaling network that is both redundant and capable of compensatory activation when targeted therapeutically.

Therapeutic attempts to inhibit tumor angiogenesis, primarily through anti-VEGF agents, have been met with variable and frequently transient success. The review discusses the mechanisms militant tumors employ to circumvent angiogenic blockade. Adaptive angiogenesis enables tumors to activate alternative pro-angiogenic pathways, effectively sidestepping VEGF inhibition. Genetic heterogeneity among tumor endothelial cells fosters a subset of resistant phenotypes that survive therapeutic pressure, sustaining neovascularization. This evolving resistance not only diminishes the efficacy of current anti-angiogenic drugs but also encourages more aggressive tumor behavior, necessitating a paradigm shift in vascular-targeted cancer therapies.

In light of these challenges, the review argues for the urgent development of more nuanced, multi-targeted therapeutic strategies. It advocates focusing on the diverse cellular origins of tumor endothelium and the molecular redundancy of angiogenic signaling pathways. Targeting the bone marrow-derived EPCs alongside local endothelial cells, modulating cancer stem cell plasticity, and intercepting transdifferentiation events stand as promising frontiers. Such approaches could effectively disrupt the vascular support system of tumors, impairing their growth and metastatic potential.

The molecular complexity of signaling in tumor angiogenesis, including VEGF, PDGF, FGF, and angiopoietin/Tie2 systems, serves not only to promote vessel growth but also to regulate vessel stability, permeability, and interaction with perivascular cells. The review elaborates on how alterations in these pathways influence tumor vascular phenotypes and how their differential expression across tumor types and stages complicates treatment. This intricate signaling milieu requires tailored interventions that can simultaneously address multiple signaling nodes to prevent compensatory mechanisms.

Importantly, the article delves into the hypoxic microenvironment typical of solid tumors, which acts as a pivotal driver in vessel formation and endothelial cell origin specification. Hypoxia-inducible factors (HIFs) activate transcriptional programs that not only upregulate VEGF but also modulate the recruitment and differentiation of diverse endothelial progenitors and supporting stromal cells. This hypoxia-induced plasticity and cell lineage flexibility present both challenges and targets for disrupting tumor vascularization.

Moreover, the review accentuates the ecological interplay between tumor cells, stromal constituents, and immune components in shaping the tumor vasculature. This bidirectional communication influences endothelial cell phenotype and function, contributing to the anomalous architecture of tumor arteries and capillaries. It sheds light on how immune cell-derived cytokines and growth factors can potentiate angiogenesis or, under certain contexts, inhibit it, outlining the complexity of immune-vascular crosstalk in cancer.

By integrating recent discoveries in endothelial cell biology and tumor physiology, the article sets a foundation for the future of anti-angiogenic therapy that is both precise and dynamic. Moving beyond the conventional monotherapies, it suggests combination regimens that concurrently target multiple cell populations and signaling pathways, potentially overcoming the formidable challenge of therapeutic resistance and tumor adaptability.

Ultimately, this comprehensive review in Genes & Diseases offers an unprecedented lens through which to view tumor angiogenesis—not simply as aberrant vessel growth but as a multifactorial, highly plastic process involving a mosaic of cellular contributors and intricate signaling networks. It brings hope that unraveling these complexities will catalyze the design of next-generation therapies capable of more effectively starving tumors and mitigating metastatic spread.

As the field advances, the translation of these insights into clinical strategies will depend on continued interdisciplinary research combining molecular biology, oncology, pharmacology, and immunology. Understanding the origins and mechanisms of tumor endothelial cells is no longer a question of curiosity—it is a vital frontier in the war against cancer.

Subject of Research: Tumor angiogenesis and endothelial cell origins
Article Title: Endothelial cell in tumor angiogenesis: Origins, mechanisms, and therapeutic implication
News Publication Date: November 1, 2025
Image Credits: Genes & Diseases
Keywords: Cancer genetics, tumor angiogenesis, endothelial cells, vascular endothelial growth factor, cancer stem cells, bone marrow-derived endothelial progenitor cells, anti-angiogenic therapy, drug resistance, hypoxia, molecular signaling pathways